Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Change in Acquisitions & Divestments: 2019-2024

Historic Change in Acquisitions & Divestments for Beam Therapeutics (BEAM) over the last 6 years, with Dec 2024 value amounting to $680.4 million.

  • Beam Therapeutics' Change in Acquisitions & Divestments rose 31.50% to $240.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $753.7 million, marking a year-over-year increase of 6.74%. This contributed to the annual value of $680.4 million for FY2024, which is 37.57% down from last year.
  • According to the latest figures from FY2024, Beam Therapeutics' Change in Acquisitions & Divestments is $680.4 million, which was down 37.57% from $1.1 billion recorded in FY2023.
  • Beam Therapeutics' 5-year Change in Acquisitions & Divestments high stood at $1.2 billion for FY2022, and its period low was $198.6 million during FY2020.
  • Moreover, its 3-year median value for Change in Acquisitions & Divestments was $1.1 billion (2023), whereas its average is $991.6 million.
  • In the last 5 years, Beam Therapeutics' Change in Acquisitions & Divestments spiked by 166.51% in 2021 and then plummeted by 37.57% in 2024.
  • Beam Therapeutics' Change in Acquisitions & Divestments (Yearly) stood at $198.6 million in 2020, then soared by 166.51% to $529.3 million in 2021, then skyrocketed by 127.60% to $1.2 billion in 2022, then dropped by 9.52% to $1.1 billion in 2023, then plummeted by 37.57% to $680.4 million in 2024.